The Rest of GNBT
Buccal Tissue Delivery
Diagnostic Kits
Wound Treatment
Ulcerative Colitis Treatment
Orthopedic Kits
Medical Services Organization (MSO)
BUCCAL TISSUE DELIVERY
This uses a spray to deliver a large molecule, in its test case, insulin, to the blood rich buccal tissue inside the cheek and from there to the blood system. My take has always been that if patients could choose between a needle (even if it is called a pen) and spritzing stuff inside the cheek, they would choose the latter every single time. Pfizer wrote off $2.8 billion on a system that sent insulin into the lungs. Patients didn’t like it, and that was that. But this does not go in the lung.
Pfizer (PFE) didn’t develop Exubera for its write-off potential, so I think the buccal spray’s ultimate value is some multiple of what Pfizer wrote off. Billions.
Generex did Phase I, II, III studies but the FDA wanted more proof. As I understand it from James Anderson M.D. of Generex, who came along after that trial, the study was poorly designed. He and others have improved the spray so that now it only takes 2 or 3 spritzes to get sufficient insulin (as opposed to 10-12), and I am confident that Anderson, former Chief of Medicine at Ely Lilly (an important insulin maker), can design a trial that can gain approval.
DIAGNOSTIC KITS
The company has developed kits that can be used in a doctor’s office to immediately advise patients if they have a disease or not. In China, for example, this may ultimately be approved for home use, so the market could be quite substantial. Kits have been developed for syphilis, malaria, HIV, hepatitis B and C, and now the company is investigating the possibility of a diagnostic kit for coronavirus.
The company has the talent to design a diagnostic kit, but in a company short of funds, I am not clear what kind of resources can be brought to bear. It might be like a university and its graduate students. Learn to write grants, find money.
WOUND TREATMENT
Generex bought Olaregen which has a liquid solution including collagen called Excellagen that is applied to the wound, and it heals faster than other methods. The product was introduced within the last year, and it is just now powering up. Sales for November were reported as $450,000 for November, but it’s on an upward trajectory. This company alone might be worth today’s market cap.
ULCERATIVE COLITIS
This treatment creates a kind of collagen bandage over the inflamed tissue in the colon, allowing it to heal. In development.
ORTHOPEDIC TOOLS AND SURGICAL KITS
Generex bought a company called Pantheon, which makes orthopedic tools and kits. It is starting to generate sales.
MEDICAL SERVICES ORGANIZATION (MSO)
Generex bought a company called Veneto, which provides services to doctors from software to x-rays to accounting. It will be reactivated in the next year.
Diabetes Initiative
In a brilliant move, the company saw that it had a couple of pieces of the diabetes puzzle, with another in the offing, and put together a plan to bring them together. It has the buccal delivery. It has the wound treatment, especially useful for diabetic patients, and it has signed a Letter of Intent to acquire ALTuCELL, in which a father, Gary Harlem, went in search of a cure for diabetes for his son. It is quite a quite clever solution.
Put these things together, plus using their MSO, and creating an HMO together with a few medical practices in Arizona and you have 25,000 to 40,000 diabetic patients who need wound treatment, and can be test subjects for bringing buccal delivery and the diabetes cure on line, and initial buyers of developed products. Positively brilliant.
So even if the insulin companies would rather their patients suffer with needles and pens, Generex can introduce the spray, and there will no way to stop its success.
